Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer | Zendy

Scott Kopetz | Zendy; Axel Grothey | Zendy; Rona Yaeger | Zendy; Eric Van Cutsem | Zendy; Jayesh Desai | Zendy; Takayuki Yoshino | Zendy; Harpreet Wasan | Zendy; Fortunato Ciardiello | Zendy; Fotios Loupakis | Zendy; Yong Sang Hong | Zendy; Neeltje Steeghs | Zendy; Tormod K. Guren | Zendy; HendrikTobias Arkenau | Zendy; Pilar GarcíaAlfonso | Zendy; Per Pfeiffer | Zendy; Sergey Orlov | Zendy; Sara Lonardi | Zendy; Elena Élez | Zendy; Tae-Won Kim | Zendy; Jan H.M. Schellens | Zendy; Christina Guo | Zendy; Asha Krishnan | Zendy; Jeroen Dekervel | Zendy; Van K. Morris | Zendy; Aitana Calvo | Zendy; Line Schmidt Tarpgaard | Zendy; Michael Braun | Zendy; Ashwin Gollerkeri | Zendy; Christopher Hunt Keir | Zendy; Kati Maharry | Zendy; Michael D. Pickard | Zendy; Janna ChristyBittel | Zendy; Lisa Anderson | Zendy; Victor Sandor | Zendy; Josep Tabernero | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Author(s) -

Scott Kopetz,

Axel Grothey,

Rona Yaeger,

Eric Van Cutsem,

Jayesh Desai,

Takayuki Yoshino,

Harpreet Wasan,

Fortunato Ciardiello,

Fotios Loupakis,

Yong Sang Hong,

Neeltje Steeghs,

Tormod K. Guren,

HendrikTobias Arkenau,

Pilar GarcíaAlfonso,

Per Pfeiffer,

Sergey Orlov,

Sara Lonardi,

Elena Élez,

Tae-Won Kim,

Jan H.M. Schellens,

Christina Guo,

Asha Krishnan,

Jeroen Dekervel,

Van K. Morris,

Aitana Calvo,

Line Schmidt Tarpgaard,

Michael Braun,

Ashwin Gollerkeri,

Christopher Hunt Keir,

Kati Maharry,

Michael D. Pickard,

Janna ChristyBittel,

Lisa Anderson,

Victor Sandor,

Josep Tabernero

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1908075

Subject(s) - cetuximab , colorectal cancer , oncology , v600e , medicine , cancer research , business , mutation , cancer , genetics , biology , gene

Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research